New drug duo aims to outsmart advanced kidney cancer
Disease control
Terminated
This study tests whether a new combination of immunotherapy drugs (botensilimab and balstilimab) works better than the current standard treatment for advanced kidney cancer. About 120 people with untreated metastatic clear cell renal cell carcinoma will take part. The goal is to …
Phase: PHASE2 • Sponsor: Michael B. Atkins, MD • Aim: Disease control
Last updated May 15, 2026 11:55 UTC